Novartis India Limited officials will meet investors and analysts at the Nuvama Emerging India CEO Forum in Mumbai on September 28, 2026. The company stated that no unpublished price sensitive information (UPSI) will be disclosed during these interactions.

Meeting details and format

The participation is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The event will feature both one-on-one and group meetings conducted in person.

Regulatory compliance and schedule

The company affirmed its commitment to fair disclosure norms by ensuring no UPSI is shared with participants. The schedule for the meeting remains subject to change due to exigencies on either side. This intimation was filed with BSE Limited on September 23, 2026.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Novartis Cosentyx (secukinumab) in polymyalgia rheumatica (PMR). The recommendation positions the drug as the first interleukin-17A (IL-17A) inhibitor licensed in Europe for this condition, targeting adults with inadequate response to steroids or relapse during steroid taper.

Clinical Trial Data

The opinion follows results from the pivotal REPLENISH Phase III trial, published in the New England Journal of Medicine and presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress. The global, randomized, double-blind study evaluated efficacy and safety across 27 countries.

Key findings from the trial include:

Patients were randomized into three arms: Cosentyx 300mg, Cosentyx 150mg, or placebo, all combined with a 24-week steroid taper regimen. Both active treatment arms met all primary and secondary endpoints, including complete sustained remission and time until additional treatment was needed through week 52.

What the Numbers Show

The data reveals a divergence between current standard-of-care limitations and the drug’s efficacy. While long-term steroid use—the existing standard—is associated with significant risks like osteoporosis and diabetes, Cosentyx delivered a steroid-sparing effect without introducing new safety signals. This suggests a potential shift in risk-benefit profiles for PMR patients, who currently face up to 40% relapse rates in the first year under conventional therapy.

Regulatory Pathway

Following the CHMP recommendation, the European Commission is expected to issue a final decision within approximately two months. If approved, Cosentyx will expand its portfolio beyond current indications in psoriatic arthritis, plaque psoriasis, ankylosing spondylosis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.

Patrick Horber, M.D., President of International at Novartis, stated that the approval would represent an important step in transforming care for those living with PMR, building on the drug’s established impact in autoimmune disease.